EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Type 2 Diabetes Remission and Long-Term Microvascular Risk: A Critical Review of Longitudinal Evidence

Josep Montserrat-Capdevila, Silvia Canivell, Pilar Vaqué Castilla

Endocrines · 2026-11-12 · 7 (4) · 74

DOI: 10.3390/endocrines7040074 ↗
AbstractBibliografische Angaben

Abstract

Background/Objectives: Type 2 diabetes (T2D) remission is increasingly attainable, but its implications for long-term microvascular risk remain uncertain. Methods: We critically appraised longitudinal reports relating achieved remission to subsequent kidney, retinal, neurologic, or composite outcomes, distinguishing temporally separated remission–outcome analyses from supportive glycemic trajectory studies with overlapping ascertainment. Evidence was checked through 5 October 2026, with an additional directly relevant CHIA companion report incorporated during revision. Eight reports were appraised (six principal direct longitudinal reports, one supportive trajectory report, and one contextual retinopathy report); overlapping CHIA populations were identified, while Danish participant overlap remains unverified. Heterogeneous exposures and estimands precluded pooling. Results: Across surgical, lifestyle, primary care and pharmacotherapy settings, several studies associated remission with lower subsequent microvascular risk. In the temporally separated CHIA analysis, remission during the first two years was associated with fewer microvascular complications over the following five years (adjusted HR 0.68, 95% CI 0.62–0.74). In Look AHEAD, remission at any assessed visit was associated with lower high-/very-high-risk chronic kidney disease (HR 0.67, 95% CI 0.52–0.87). Trajectory analyses provide complementary but temporally less secure evidence and should not be equated with medication-free remission. Conclusions: Achieved T2D remission is a potentially informative prognostic state; evidence concerning duration is suggestive but definition- and design-dependent. Neither a causal effect of remission itself nor normalization of prior microvascular risk has been established.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →